中國東方航空股份(00670.HK)擬發行不超100億元債券
格隆匯3月5日丨中國東方航空股份(00670.HK)發佈公吿,公司2021年公開發行公司債券(第一期)為第三期發行,本期債券發行規模為不超過100億元(含100億元),本期債券分為兩個品種,品種一為10(5+5)年期固定利率品種,附第5年末發行人調整票面利率選擇權和投資者回售選擇權(以下簡稱“品種一”);品種二為6(3+3)年期固定利率品種,附第3年末發行人調整票面利率選擇權和投資者回售選擇權,兩個品種間可進行雙向回撥,回撥比例不受限制。
本期債券品種一的票面利率詢價區間為3.20%-4.20%,品種二的票面利率詢價區間為3.00%-4.00%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.